China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025)
China Pharma Holdings' (CPHI) quarterly Asset Writedowns and Impairment came in at -$507897.0 in Q4 2025, down 10.83% YoY from -$569559.2 in Q4 2024, and down 2107.34% on a QoQ basis from $25302.0 in Q3 2025.
China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025) Analysis & Trends
China Pharma Holdings (CPHI) has 11 years of Asset Writedowns and Impairment data on file, last reported at -$507897.0 in Q4 2025.
- Quarterly Asset Writedowns and Impairment fell 10.83% year-over-year to -$507897.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$267184.0 (up 41.09% YoY) and the FY2025 annual result came in at -$1018.0, down 117.85% from the prior year.
- Asset Writedowns and Impairment slipped to -$507897.0 in Q4 2025, from $25302.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $213379.0 in Q1 2025 to a low of -$507897.0 in Q4 2025.
- A 5-year average of -$50769.3 and a median of -$3212.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment slumped 2924.19% — and 2025, when it jumped 10428.12%.
- Tracing CPHI's Asset Writedowns and Impairment over 5 years: stood at -$250622.0 in 2021, then soared by 95.96% to -$10136.0 in 2022, then soared by 260.09% to $16227.0 in 2023, then tumbled by 2924.19% to -$458282.0 in 2024, then fell by 10.83% to -$507897.0 in 2025.
- The last three Asset Writedowns and Impairment figures came in at -$507897.0 (Q4 2025), $25302.0 (Q3 2025), and $2032.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | China Pharma Holdings | 41.38 Mn | 41.08 Mn | 83,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -507,897.00 |
| Dec 31, 2025 | -507,897.00 |
| Sep 30, 2025 | 25,302.00 |
| Sep 30, 2025 | 25,302.00 |
| Jun 30, 2025 | 2,032.00 |
| Jun 30, 2025 | 2,032.00 |
| Mar 31, 2025 | 213,379.00 |
| Mar 31, 2025 | 213,379.00 |
| Dec 31, 2024 | -458,282.00 |
| Dec 31, 2024 | -458,282.00 |
| Sep 30, 2024 | -1,656.00 |
| Sep 30, 2024 | -1,656.00 |
| Jun 30, 2024 | 8,476.00 |
| Jun 30, 2024 | 8,476.00 |
| Mar 31, 2024 | -2,066.00 |
| Mar 31, 2024 | -2,066.00 |
| Dec 31, 2023 | 16,227.00 |
| Dec 31, 2023 | 16,227.00 |
| Sep 30, 2023 | -18,212.00 |
| Sep 30, 2023 | -18,212.00 |